febuxostat / Generic mfg. |
ACTRN12612000434897: To compare the efficacy & safety profile of Febuxostat with Allopurinol in
local Pakistani hyperuricemic patients. |
|
|
| Recruiting | 4 | 120 | | | PharmEvo (Pvt.) Ltd., PharmEvo (Pvt.) Ltd. | Hyperuricemia, Gout | | | | |
ACTRN12616000959471: A multicentre study of the dose concentration response of febuxostat in patients with chronic gout. |
|
|
| Recruiting | 4 | 120 | | | St Vincent's Hospital, Clinical Pharmacology Lexy Davies Trust Fund | Gout | | | | |
ChiCTR-TTRCC-14005168: Pharmacokinetics and Tolerability of Febuxostat Tablets after Oral Administration in Healthy Chinese Volunteers: A Randomized, Open-Label, Single- and Multiple-Dose Study |
|
|
| Completed | 4 | 36 | | administer febuxostat 40mg as a single dose (day1) and multiple doses (days 4–9) ;administer febuxostat 80mg as a single dose (day1) and multiple doses (days 4–9) ;received a single dose of 120mg febuxostat | the First Affiliated Hospital, College of Medicine, Zhejiang University; None, Zhejiang Jianfeng Pharmaceutical CO., LTD | Healthy Volunteers | | | | |
| Ongoing | 4 | 4706 | Europe | Feboxostat Trade Name: Adenuric, Allopurinol, Adenuric, Allopurinol, Adenuric, Allopurinol | University of Dundee, , Menarini | Chronic symptomatic hyperuricaemic | | | | |
2012-001858-25: A clinical study on the therapeutic efficacy and safety of Febuxostat and Allopurinol on serum urate concentration in subjects suffering from hyperuricemia and gout |
|
|
| Ongoing | 4 | 330 | Europe | Febuxostat, Allopurinol, Colchicine, ADENURIC, ZYLORIC, Colchicina Lirca, ADENURIC, ZYLORIC, Colchicina Lirca | MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A., MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A., MIOL - Menarini International Operations Luxembourg S.A. | hyperuricemia and gout | | | | |
ChiCTR-IPR-17011837: The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese asymptomatic hyperuricemic patients with chronic kidney disease |
|
|
| Recruiting | 4 | 100 | | febuxostat ;allopurinol | the Affiliated Hospital of Qingdao University; the Affiliated Hospital of Qingdao University, raise independently | Hyperuricemia | | | | |
ChiCTR1800019352: A randomized controlled open-label trial for the efficacy and safety of low dose febuxostat and benzbromarone in gout patients |
|
|
| Completed | 4 | 240 | | febuxostat 20mg/d p.o. + sodium bicarbonate 1g qd p.o. ;benzbromarone 25mg qd p.o. + sodium bicarbonate 1g qd p.o. | the Affiliated Hospital of Qingdao University; the Affiliated Hospital of Qingdao University, The study of molecular typing of gout based on omics characteristic spectrum | gout | | | | |
ChiCTR1800018160: Comparison of the efficacy of fenofibrate combined with febustat and benzbromarone in the treatment of gout with hypertriglyceridemia |
|
|
| Recruiting | 4 | 804 | | Febuxostat + fenofibrate: febuxostat 20mg / day + fenofibrate capsule 200mg /day, oral,at breakfast ;Benzobromide tablets + fenofibrate: benzbromarone 25mg /day + fenofibrate capsules 200mg / day, oral,at breakfast | Affiliated Hospital of Qingdao University; Affiliated Hospital of Qingdao University,Shandong Gout Clinical Medical Center, Provided by the tester | gout | | | | |
ChiCTR1800020310: The effects of febuxostat versus allopurinol on oxidative stress in Chinese asymptomatic hyperuricemic patients with chronic kidney disease |
|
|
| Recruiting | 4 | 371 | | febuxostat ;allopurinol ;none | the Affiliated Hospital of Qingdao University; the Affiliated Hospital of Qingdao University, raise independently | Hyperuricemia | | | | |
ChiCTR-RIC-17011687: A single-center, prospective cohort study of the effects of Febuxostat Tablets on insulin resistance and islet beta cells function in patients with hyperuricemia with different glucose metabolic status |
|
|
| Not yet recruiting | 4 | 120 | | patients treated with Febuxostat Tablets ;patients treated without Febuxostat Tablets | Shanghai Jiao Tong University Affiliated Sixth People's Hospital; Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Jiangsu Hengrui pharmaceutical Limited by Share Ltd | hyperuricemia | | | | |
ChiCTR1800017922: Effects of Febuxostat on improving glucose and lipid metabolic, and anti-arteriosclerosis in asymptomatic hyperuricemia patients |
|
|
| Recruiting | 4 | 300 | | Only have low purine diet ;take febuxostat orally | The Affiliated Huai'an 1st People's Hospital of Nanjing Medical University; The Affiliated Huai'an 1st People 's Hospital of Nanjing Medical University, Enterprises aid research | Asymptomatic hyperuricemia | | | | |
ChiCTR1900028169: A clinical study for febuxostat with stepwise dose in the prevention of gout flares |
|
|
| Recruiting | 4 | 275 | | stepwise dose increase of febuxostat ;febuxostat+colchicine ;febuxostat40mg/d | Anqing Hospital Affiliated to Anhui Medical University; Anqing Hospital Affiliated to Anhui Medical University, Scientific research foundation of anhui medical university | Gout | | | | |
ChiCTR1900021469: The effect of febuxostat in Tibetan gout patients: An observational study |
|
|
| Recruiting | 4 | 70 | | 无 | Hospital of the People's Government of Tibet Autonomous Region in Chengdu Office; Hospital of the People's Government of Tibet Autonomous Region in Chengdu Office, planning funds offered by Sichuan provincial health and family planning commission and supporting funds offered by ourself hospital | gout and uric acid | | | | |
ChiCTR1800015509: Clinical Study on the Treatment of simple Obesity with Hyperuricemia by Febuxostat Tablets |
|
|
| Recruiting | 4 | 150 | | febuxostat tables ;Lifestyle | Chengdu University of Traditional Chinese Medicine; Chengdu University of Traditional Chinese Medicine, JIANG SU HENG RUI MEDICINE CO,.LTD | simple obesity with asymptomatic hyperuricemia | | | | |
2020-005730-15: Research into continuation or cessation of urate lowering therapies in gout patients in remission. Onderzoek met urinezuurverlagende therapie bij jicht. Levenslang doorgaan of is (tijdelijk) stoppen mogelijk? |
|
|
| Ongoing | 4 | 310 | Europe | Tablet, Allopurinol, Desuric, Adenuric | Sint Maartenskliniek, ZonMw /ZE&GG, Sint Maartenskliniek | Gout, arthritis urica, Gout, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2020-005721-82: The Gout TrEatment STrategy Project (GO TEST) Overture trial |
|
|
| Ongoing | 4 | 310 | Europe | Tablet, Zyloric, Adenuric 80 mg, Desuric | VieCuri, ZonMW, ReumaNederland | gout, gout, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
ChiCTR2100044828: Effects of different types of uric acid lowering drugs on gout flare |
|
|
| Recruiting | 4 | 150 | | febuxostat(40mg/d,4 weeks) or allopurinol (200mg/d, 4 weeks) ;benzbromarone(50mg/d,4 weeks) | The First Affiliated Hospital of University of Science and Technology of China; The First Affiliated Hospital of University of Science and Technology of China, The patient bears the cost of the test | Gout | | | | |
ChiCTR2000034138: Randomized, double-blind, double-simulated, parallel-controlled clinical trials of the efficacy and safety of Medicinal Charcoal Tablets in the treatment of primary gout with hyperuricemia |
|
|
| Not yet recruiting | 4 | 168 | | Febuxostat 20mg, 2 tablets, qd; medicinal carbon tablets analog, 8 tablets, tid; oral ;Febuxostat 20mg, 1 tablet, febuxostat analog tablet, 1 tablet, qd; medicinal carbon tablets, 5 tablets, medicinal carbon tablets analog, 3 tablets, tid; oral ;Febuxostat 20mg, 1 tablet, febuxostat analog tablet, 1 tablet, qd;medicinal carbon tablets, 8 tablets, tid; oral ;Febuxostat 20mg, 1 tablet, febuxostat analog tablet, 1 tablet, qd; medicinal carbon tablets analog, 8 tablets, tid; oral | Affiliated Hospital of Qiingdao University; Affiliated Hospital of Qingdao University, Provided by the tester | gout | | | | |
ChiCTR2200067196: Effect of diffrent dose of febuxostat on renal function in elderly patients with chronic kidney disease and hyperuricemia |
|
|
| Completed | 4 | 120 | | Febuxostat 20 mg/d ;Febuxostat 40 mg/d ;Diet and lifestyle intervention | Zhejiang Provincial People's Hospital; Zhejiang Provincial People's Hospital, Self-funded | hyperuricemia | | | | |
ChiCTR2000038289: A randomized, controlled, single center clinical trial of total glucosides of paeony in the prevention of gout |
|
|
| Recruiting | 4 | 120 | | Paeonia total glycosides capsule 0.6g Tid ;Blank control group ;Febuxostat capsules 20mg Qd + total glucosides of paeony capsules 0.6g tid ;Febuxostat capsules 20mg Qd | The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) Department of Rheumatology and Immunology; The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Ningbo Lihua Pharmaceutical Co., Ltd. | Gout | | | | |
ChiCTR2100042424: The efficacy and safety of chitosan oligosaccharide in treatment of Chinese primary gout with hyperuricemia patients: a prospective, randomized controlled study |
|
|
| Recruiting | 4 | 150 | | Febuxostat 20mg qd, placebo 6g, bid ;Febuxostat 20mg qd, Kesuanping 6g, bid | Affiliated Hospital of Qiingdao University; Affiliated Hospital of Qiingdao University, Provided by the Sponsor | gout | | | | |
ChiCTR2100050749: Comparative study on the effectiveness of tart cherry citrate effervescent tablets, citrate effervescent tablets and sodium bicarbonate in alkalizing urine of patients with primary gout with hyperuricemia |
|
|
| Recruiting | 4 | 270 | | Febuxostat 20mg qd + citrate effervescent tablets 3.5g bid (initial treatment); Febuxostat 40mg qd + citrate effervescent tablets 3.5g bid (adjusted based on urate level) ;Febuxostat 20mg qd + sodium bicarbonate 1g tid (initial treatment); Febuxostat 40mg qd + sodium bicarbonate 1g tid (adjusted based on urate level) ;Febuxostat 20mg qd + tart cherrycitrate effervescent tablets 3.5g bid (initial treatment); Febuxostat 40mg qd + tart cherry citrate effervescent tablets 3.5g bid (adjusted based on urate level) | Affiliated Hospital of Qiingdao University; Affiliated Hospital of Qingdao University, Provided by the tester | gout | | | | |
ChiCTR2000035778: Long-term safety of urate-lowering drugs and their protective effects on important organs |
|
|
| Not yet recruiting | 4 | 450 | | Allopurinol is recommended to start at 100mg and 50mg for patients with renal insufficiency ;Febuxostat start at 20mg ;Benzbromarone start at 25mg | Huashan Hospital, Fudan University; Huashan Hospital, Fudan University, Shanghai Shenkang Hospital Development Center | Gout/Hyperuricemia | | | | |
2021-002185-40: Allopurinol and Febuxostat Treatment in Patients with Adenine Phosphoribosyltransferase Deficiency: A Clinical Trial |
|
|
| Ongoing | 4 | 10 | RoW | Tablet, Uloric, Allopurinol Alvogen | Landspitali - The National University Hospital of Iceland, Icelandic Research Fund | Adenine phosphoribosyltransferase deficiency, Adenine phosphoribosyltransferase deficiency is a hereditary disorder causing kidney stones and kidney failure in untreated patients., Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | | | | |
| Enrolling by invitation | 4 | 2 | RoW | Febuxostat 80 MG Oral Tablet or Allopurinol 300 MG Oral Tablet | Medical Practice Prof D. Ivanov | Gout, CKD Stage 1-4, SUA Level (>8 mg/dL; 480 µmol/L) | 12/22 | 12/22 | | |
LUMINA, NCT03200210: Lowering-hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients |
|
|
| Recruiting | 4 | 548 | RoW | Febuxostat, Febuxostat Tablets, Placebo | Sun Yat-sen University | Hyperuricemia | 12/22 | 12/22 | | |
ChiCTR2200055197: Comparative trial on effectiveness and safety of benzbromarone and febuxostat in lower-urate therapy of gout patients with combined types |
|
|
| Recruiting | 4 | 250 | | Febuxostat 25mg qd + citrate mixture 3.5g bid (initial treatment); Febuxostat 40mg qd + citrate mixture 3.5g bid(adjusted based on urate level) ;Febuxostat 25mg qd + citrate mixture 3.5g bid (initial treatment); Febuxostat 40mg qd +benzbromarone 25mg qd + citrate mixture 3.5g bid(adjusted based on urate level) | Affiliated hospital of Qingdao University; Affiliated Hospital of Qingdao University, Shandong Provincial Key Laboratory of Metabolic Diseases | gout | | | | |
NCT05474560: Febuxostat Versus Allopurinol on Hepatic Steatosis in MAFLD Patients |
|
|
| Completed | 4 | 90 | RoW | Allopurinol (100 mg/day) plus lifestyle intervention, Allopurinol group, Febuxostat 40 mg plus lifestyle intervention, Febuxostat group, Life style intervention | Ain Shams University | Non-Alcoholic Fatty Liver Disease, Hyperuricemia | 01/23 | 01/23 | | |
ChiCTR2200066023: Clinical trial of Aixite medicinal charcoal tablets in preventing acute attack during the treatment of primary gout and reducing uric acid |
|
|
| Not yet recruiting | 4 | 300 | | Febuxostat 40mg+medicinal carbon tablets ;Febresta 40mg qd+colchicine 0.5mg qd ;Febuxostat 40mg qd | Affiliated Hospital of Qingdao University; Affiliated Hospital of Qingdao University, Provided by the experimental party | gout | | | | |
ChiCTR2200057996: Studies on enzyme activity, metabolomics, gene expression and gene polymorphism of phase I and phase II drug metabolism represented by CYP3A4, UGT and CES in obese people |
|
|
| Not yet recruiting | 4 | 132 | | Sixteen males are planned to be enrolled. Subjects took 2mg midazolam orally on an empty stomach in D1 to detect midazolam concentration ;Sixteen males are planned to be enrolled. Subjects took febuxostat 80mg orally on an empty stomach D1 to detect febuxostat concentration ;A total of 100 healthy subjects were included in the phase 1 clinical trial. 5 ml of venous blood was collected for the detection of drug metabolism enzyme related gene polymorphism, gene expression and metabonomics | Beijing Friendship Hospital, Capital Medical University; Beijing Friendship Hospital, Capital Medical University, Self-raised funds | Obesity | | | | |
ChiCTR2300071874: The effect of small molecule alkaline water in combination with febuxostat on serum urate in patients with gout:a randomized, placebo-controlled clinical trial |
|
|
| Recruiting | 4 | 224 | | Febuxostat+Purified Water: Febuxostat 20/40 mg qd +Purified water 6 bottles qd; ;Febuxostat+C-cell vitality water: Febuxostat 20/40 mg qd +C-cell vitality water 6 bottles qd; | The Affiliated Hospital of Qingdao University; The Affiliated Hospital of Qingdao University, Provided by the experimental party | Gout | | | | |
ChiCTR2300078984: Randomized, controlled, multicenter clinical study of rebamipide in the prevention of gout attack |
|
|
| Recruiting | 4 | 195 | | Febuxostat 20 mg bid + rebamipide 0.1 g tid; Febuxostat 20 mg bid + colchicine tablets 0.5 mg qd; Febuxostat 20 mg bid | Anqing Hospital Affiliated to Anhui Medical University; Anqing Hospital Affiliated to Anhui Medical University, self-finance | gout | | | | |
IRCT20190727044343N1: The effect of febuxostat against lung injury induced by COVID-19 virus in infected patients: A clinical trial study |
|
|
| Active, not recruiting | 3 | 60 | Mazandaran | febuxostat - Ipsen, Menarini, Generic mfg. | Ipsen, Menarini, Generic mfg. | COVID-19 | | | | |
2020-004766-19: Non-inferiority study of a new therapeutic strategy for gout: immediate prescription of a hypouricemia treatment, febuxostat, compared to its deferred administration. Etude de non-infériorité d'une nouvelle stratégie thérapeutique de la goutte : prescription immédiate d'un traitement hypouricémiant, le fébuxostat, comparée à son administration différée |
|
|
| Not yet recruiting | 3 | 128 | Europe | ADENURIC, AMM EU/1/08/447/024, Film-coated tablet, ADENURIC (fébuxostat) 80 mg | University Hospital Centre of Rouen, University Hospital Centre of Rouen | Patients with gout attacks Malades atteints d'une crise de goutte, Gout disease Maladie de la goutte, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
NCT05007392: A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout |
|
|
| Completed | 3 | 451 | RoW | Dotinurad, FYU-981, Febuxostat, Dotinurad Matched Placebo, Febuxostat Matched Placebo | Eisai Co., Ltd. | Gout | 06/23 | 06/23 | | |
NCT06139393: Clinical Study of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults |
|
|
| Not yet recruiting | 3 | 750 | NA | HR091506 tablets + placebo of febuxostat tablets, febuxostat tablets + placebo of HR091506 tablets | Jiangsu HengRui Medicine Co., Ltd. | Gout With Hyperuricemia in Adults | 11/24 | 06/25 | | |
NCT06414837: Clinical Trial of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults |
|
|
| Not yet recruiting | 3 | 434 | NA | HR091506 tablets + placebo of febuxostat tablets, febuxostat tablets + placebo of HR091506 tablets | Jiangsu HengRui Medicine Co., Ltd. | Gout With Hyperuricemia in Adults | 06/26 | 06/26 | | |
FEFACRIGOU, NCT05109936: Immediate Prescription of a Hypouricemic Treatment, Febuxostat, Compared to Its Delayed Administration |
|
|
| Not yet recruiting | 3 | 128 | NA | Adenuric | University Hospital, Rouen | Gout | 08/25 | 08/25 | | |
EPIC, NCT05815901: A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients |
|
|
| Recruiting | 3 | 588 | RoW | Epaminurad 6 mg, Epaminurad 9 mg, Febuxostat 40 mg, Febuxostat 80 mg, Epaminurad 6 mg placebo, Epaminurad 9 mg placebo, Febuxostat 40 mg placebo, Febuxostat 80 mg placebo | JW Pharmaceutical | Gout | 08/25 | 08/25 | | |
NCT06603142: Phase II/III Study of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and Hyperuricemia |
|
|
| Active, not recruiting | 2/3 | 636 | RoW | Febuxostat 20MG Tablets, Febuxostat 20MG Placebo, AR882 25MG, AR882 12.5MG, AR882 25MG Placebo, AR882 12.5MG Placebo, Febuxostat 40MG Tablets, Febuxostat 40MG Placebo | Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd | Primary Gout, Hyperuricemia | 04/26 | 04/26 | | |
NCT04772352: Effects of Febuxostat for Lowering Uric Acid in NAFLD Patients With Gout |
|
|
| Not yet recruiting | 2 | 200 | RoW | febuxostat treatment, lifestyle intervention | Ningbo No. 1 Hospital | Nonalcoholic Fatty Liver Disease | 08/21 | 03/22 | | |
NCT05513976: Clinical Study of SHR4640 Tablets Combined With Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia |
|
|
| Not yet recruiting | 2 | 129 | NA | SHR4640 tablet, febuxostat tablet, SHR4640 placebo tablet | Jiangsu HengRui Medicine Co., Ltd. | Primary Gout and Hyperuricemia | 05/23 | 09/23 | | |
NCT05574036: Comparative Study Between Febuxostat Versus Vitamin E in Non-alcoholic Steatohepatitis Patients With Hyperuricemia |
|
|
| Recruiting | 2 | 70 | RoW | Febuxostat 80 MG Oral Tablet, Andouristat 80 mg, Staturic 80 mg, vit E, Vitamin E 400 mg | Tanta University | Non Alcoholic Steatohepatitis, Hyperuricemia | 05/24 | 12/24 | | |
NCT06501534: A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects |
|
|
| Active, not recruiting | 2 | 84 | RoW | Febuxostat, IBI128 | Innovent Biologics (Suzhou) Co. Ltd. | Gout, Hyperuricemia | 01/25 | 02/25 | | |
| Recruiting | 1/2 | 10 | | | St Vincent's Hospital, Sydney, Clinical Pharmacology Lexy Davies Trust Fund | Chronic gout | | | | |
ACTRN12612001107819: Febuxostat-thiopurine combination therapy in patients with moderately severe inflammatory bowel disease |
|
|
| Not yet recruiting | 1 | 6 | | | Prof Tim Florin | inflammatory bowel disease | | | | |
ChiCTR-TTRCC-14004288: Pharmacokinetics and Bioequivalence study of Febuxostat Tablets in Healthy Chinese male Volunteers |
|
|
| Completed | 1 | 24 | | febuxostat(newly developed formulation or established branded formulation) | West China Hospital, Sichuan University; Furuikangzheng Medical Research Institute, primary and secondary sponsor | Pharmacokinetic Properties | | | | |
| Completed | 1 | 60 | | In the fasting state, single and multiple oral doses of 40mg firstly, then single and multiple oral doses of 80mg, finally single oral dose of 120mg ;In the fasting state, single and multiple oral doses of 80mg firstly, then single oral dose of 120mg, finally singl and multiple oral doses of 40mg ;In the fasting state, single oral dose of 120mg firstly, then single oral dose of 40mg, finally single and multiple oral doses of 40mg ;Single oral dose of 80mg in the fasting state, then single oral dose of 80mg in the fed state ;Single oral dose of 80mg in the fed state, then single oral dose of 80mg in the fasting state | The first affiliated hospital, School of Medicine, Zhejiang University; Jiang Su Heng Rui Co. LTD, Provided by Jiang Su Heng Rui Co. LTD | gout | | | | |
ChiCTR-IIC-16007794: Febuxostat for prevention of cardiovascular, cerebrovascular and renal events in chronic kidney disease patients with hyperuricemia: A Multicenter, prospective, randomized, double blind, placebo-controlled study |
|
|
| Not yet recruiting | 1 | 400 | | febuxostat ;Placebo | Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University; Kidney Disease Center, the First Affiliated Hospital, College of Medicine, Zhejiang University, Manufacturer Sponsorship | chronic kidney disease patients with hyperuricemia | | | | |
NCT05347498: A Trial of HR091506 Tablets in Treatment of Primary Gout With Hyperuricemia in Adults |
|
|
| Not yet recruiting | 1 | 90 | NA | HR091506 tablets + placebo of febuxostat tablets, febuxostat tablets + placebo of HR091506 tablets | Jiangsu HengRui Medicine Co., Ltd. | Primary Gout With Hyperuricemia in Adults | 07/22 | 07/22 | | |
NCT05324423: To Evaluate Drug Interactions Between XNW3009, Febuxostat, and Colchicine in Patients With Gout |
|
|
| Recruiting | 1 | 20 | RoW | Colchicine, Febuxostat、XNW3009 | The Affiliated Hospital of Qingdao University | Gout | 08/22 | 09/22 | | |
ChiCTR2200058093: Effect of Jianpi Qushi Recipe on hyperuricemia patients and the serum levels of inflammatory cytokines |
|
|
| Not yet recruiting | 1 | 168 | | Oral Jianpi Qushi prescription + lifestyle adjustment (diet, exercise) ;Oral febuxostat treatment+lifestyle adjustment (diet, exercise) | Tianjin First Central Hospital; Tianjin First Central Hospital, Self-raised | hyperuricemia | | | | |
NCT06525974: Clinical Study to Evaluate the Possible Efficacy and Safety of Febuxostat in Patients With Ulcerative Colitis Treated With Mesalamine |
|
|
| Not yet recruiting | 1 | 46 | NA | Febuxostat, Mesalamine | Tanta University | Ulcerative Colitis | 09/26 | 12/26 | | |
NCT06233162: Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets |
|
|
| Not yet recruiting | 1 | 46 | NA | Febuxostat-Test product, Febuxostat-Reference product | Bio-innova Co., Ltd | Healthy Subjects | 10/24 | 10/24 | | |
ChiCTR2300070861: Clinical study on Jianpi Zhishui Granules treating gouty nephropathy (spleen deficiency and dampness resistance type) |
|
|
| Not yet recruiting | 1 | 40 | | Oral administration of febuxostat tablets and Jianpi Xiaoshi granules ;Oral febuxostat tablets | The First Affiliated Hospital of Yunnan University of Chinese Medicine; Yunnan Hospital of Traditional Chinese Medicine, Department of Rheumatology, Yunnan Hospital of Traditional Chinese Medicine | gouty nephropathy | | | | |
| Recruiting | N/A | 120 | | Westen medical treatmentswith uricosuric ;Routine treatment of Westen medicine | The Affiliated Hospital of Qingdao University; The Affiliated Hospital of Qingdao University, Self-reliance | gout | | | | |
ChiCTR-TTRCC-13003760: Comparative Fasting Bioavailability of Two Febuxostat Formulations in Healthy Male Chinese Volunteers: An Open-Label, Randomized, Single-Dose, Two-Way Crossover Study |
|
|
| Completed | N/A | 24 | | 1st period, reference formulation-80mg; 2nd period, test, 80mg ;1st period, test formulation-80mg; 2nd period, reference, 80mg | First Affiliated Hospital, College of Medicine, Zhejiang University; Zhejiang Jianfeng Pharmaceutical Co., Ltd., Zhejiang Jianfeng Pharmaceutical Co., Ltd. | Healthy Volunteers | | | | |
ChiCTR1800015962: Study of the Relationship between Urolithic Lower Urinary Acid Treatment and Inflammation Duration in the Acute Phase of Gout |
|
|
| Not yet recruiting | N/A | 140 | | Diclofenac 75mg, b.i.d ;Diclofenac 75mg, b.i.d, + Febuxostat 40mg/d | Shenzhen Traditional Chinese Medicine Hospital, the fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen; The Second Affiliated Hospital Guiyang College of Traditional Chinese Medicine, This study was funded by the Sanming Project of Medicine in Shenzhen | Gout | | | | |
ChiCTR2000032908: Effects of urine alkalization in gout patients: a prospective, randomized controlled trial |
|
|
| Completed | N/A | 200 | | Urine alkalization control drugs sodium bicarbonate were taken for one month at a dose of 3 × 1.0 g/day,at the same time, the uric acid-lowering drug febuxostat tablets was taken (40 mg, qd). ;Urine alkalization control drugs sodium hydrogen citrate were taken for one month at a dose of 3 × 2.5 g/day,at the same time, the uric acid-lowering drug febuxostat tablets was taken (40 mg, qd). | Affiliated Hospital of Qingdao University; Affiliated Hospital of Qingdao University, National key research and development program | Gout | | | | |
ChiCTR2000038137: The clinical study of uric acid-lowering therapy for blood pressure control in patients with prehypertension and hyperuricemia |
|
|
| Recruiting | N/A | | | Febuxostat ;Nil | Deyang People's Hospital; Deyang People's Hospital, Health Hommission of Sichuan Provincial | Prehypertension | | | | |
ChiCTR2000036918: Evaluation of the clinical efficacy of the comprehensive regimen of traditional Chinese medicine in the treatment of chronic kidney disease with hyperuricemia |
|
|
| Recruiting | N/A | 150 | | traditional Chinese medicine ;Febuxostat ;Chinese medicine plus febuxostat group | Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine; Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai Municipal Health and Family Planning Commission | CKD HUA | | | | |
ChiCTR1800020315: Study for the effectiveness of different courses of low-dose colchicine for preventing acute flares during urate lowering therapy by febuxostat |
|
|
| Recruiting | N/A | 162 | | 4 weeks of low-dose colchicine for preventing ;12 weeks of low-dose colchicine for preventing ;24 weeks of low-dose colchicine for preventing | The Second Affiliated Hospital, Zhejiang University School of Medicine; The Second Affiliated Hospital, Zhejiang University School of Medicine, Self-funding | Gout | | | | |
ChiCTR1900028684: Follow-up study for the curative effect of uric acid-reducing treatment in patients with hyperuricemia |
|
|
| Not yet recruiting | N/A | 160 | | Treatment with benzbromarone ;Treatment with febuxostat / allopurinol ;Treatment with benzbromarone ;Treatment with febuxostat / allopurinol ;Treatment with benzbromarone ;Treatment with febuxostat / allopurinol ;Treatment with benzbromarone ;Treatment with febuxostat / allopurinol | Shanghai Jiao Tong University Affiliated Sixth People's Hospital; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, No funding involved | hyperuricemia | | | | |
ChiCTR1900025510: Urate-lowering therapy (ULT) on the progression of chronic kidney disease in stages 2–4 patients with hyperuricemia:a prospective, multi-center, open-label clinical study |
|
|
| Recruiting | N/A | 288 | | Febuxostat tablets | Xinhua Hospital Affiliated To Shanghai Jiaotong University School of Medicine; Xinhua Hospital Affiliated To Shanghai Jiaotong University School of Medicine, self-raised | CKD stages 2-4 patients with hyperuricemia | | | | |
ChiCTR2000038654: Effect of low-dose febuxostat combined with colchicine on acute attack of gouty arthritis |
|
|
| Not yet recruiting | N/A | 200 | | Give etoricoxib 120 mg qd*5 days within 72 hours of acute gout attack; Febuxostat 20mg qd+colchicine 0.5mg qd*3 months; For acute attacks of gouty arthritis, start the treatment for 1, 3, 5, 7 days and 2 weeks, 1 month, and 3 months to do the joint pain VAS score, and check the inflammation& ;Give etoricoxib 120 mg qd*5 days within 72 hours of acute gout attack; Colchicine 0.5mg qd*3 months; Acute onset of gout, pain relief for 2 weeks, start to give febuxostat 20mg qd to 3 months; For acute attacks of gouty arthritis, start treatment for 1, 3, 5, 7 days, and 2 weeks, 1 month | Center for Endocrine Metabolism and Immune Diseases, Luhe Hospital, Capital Medical University; Center for Endocrine Metabolism and Immune Diseases, Lu He Hospital, Capital Medical University, Center for Endocrine Metabolism and Immune Diseases, Luhe Hospital, Capital Medical University | gout | | | | |
ChiCTR2000036866: A clinical study on precise intervention of ocular uric acid based on metabonomics for diabetic retinopathy |
|
|
| Not yet recruiting | N/A | 60 | | Control ;benzene bromine Malone ;Febuxostat | Shanghai General Hospital; Shanghai General Hospital, Scientific research project funds | Diabetic retinopathy | | | | |
ChiCTR2200061620: Decrease in serum urate level is associated with decrease of blood pressure in young adults gout patients: a prospective, randomized controlled trial |
|
|
| Recruiting | N/A | 400 | | Febuxostat 20~80 mg/day or benzbromarone 25~50 mg/day while without anti-hypertension drugs ;Without urate-lowering therapy while without anti-hypertension drugs | the Affiliated Hospital of Qingdao University; the Affiliated Hospital of Qingdao University, National Natural Science Foundation of China (81900636、81770869) | Gout | | | | |
ChiCTR2200056024: Clinical observation of Jianpi Bushen Xiezhuo fang decoction for the intermittent gout patients with Pixu Shizhu zheng |
|
|
| Not yet recruiting | N/A | 90 | | Jianpi Bushen Xiezhuo Fang ;Febuxostat ;benzbromarone | Chongqing Hospital of Traditional Chinese Medicine; Chongqing Hospital of Traditional Chinese Medicine, Scientific research project of Chongqing Health and Family Planning Commission | gout | | | | |
ChiCTR2100049048: A randomized controlled trial evaluating the jiangniaosuan formulation as a treatment for hyperuricemic nephropathy at CKD stages 3-4 patients |
|
|
| Not yet recruiting | N/A | 118 | | Jiangniaosuan formulation+Febuxostat+Basic treatment ;Febuxostat+Basic treatment | Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine; Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Science and Technology Commission of Shanghai Municipality | hyperuricemic nephropathy at CKD stages 3-4 | | | | |
ChiCTR2300073394: Clinical Intervention Trial of Decreasing Uric Acid and Protecting Kidney in Healthy Physical Examiners with Hyperuricemia |
|
|
| Not yet recruiting | N/A | 100 | | Control group: Participants were instructed to maintain a healthy lifestyle and limit their intake of high purine diets. A follow-up examination was conducted after twelve weeks. After reexamination, it is recommended that patients receive clinical standardized treatment for those who meet clinical treatment standards. ;Intervention group: 1. According to the "Chinese HUA and Gout Diagnosis and Treatment Guidelines (2019)" , guide all SUA > 420 μmol/L. Patients with mol/L maintain a healthy lifestyle, including weight control, limiting alcohol and high purine and fructose intake; Encourage the intake of dairy products, vegetables, and moderate drinking water; Do not recommend or limit the intake of soy products. 2. Patient's blood uric acid level > 540 μmol/L, use Febuxostat, the initial dose is 20 mg/time, once a day, and recheck for 2 weeks. According to the blood uric acid value, 20 mg/time can be increased, and the maximum daily dose is 80mg. Take continuously for 4 weeks. The goal is to control blood uric acid levels below 420 μmol/L. 3. Patients with a morning urine pH value of < 6.0 should take sodium bicarbonate at a dose of 1 g/time, twice a day, and drink no less than 2000mL of water per day. It is recommended to use a simple urine pH meter to self monitor the urine pH value, with the goal of maintaining the urine pH between 6.2 and 6.9. If self monitoring is not possible, the urine pH value should be rechecked at least every two weeks. 4. Regular follow-up, including blood uric acid levels and urine pH value. 5. According to the usual onset time of clinical uric acid lowering therapy, this intervention trial lasts for 42 weeks. Check and record all indicators before and after intervention, and keep two urine samples. The intervention experiment is over, and all clinical work continues according to diagnostic and treatment standards. | Xuzhou Central Hospital; Xuzhou Central Hospital, National Natural Science Foundation of China (82070854) | Renal Injury | | | | |
ChiCTR2100045183: The effect of alkalized urine on kidney stones in patients with gout: a randomized controlled double-blind trial |
|
|
| Recruiting | N/A | 98 | | Sodium Bicarbonate + Febuxostat ;Placebo+Sodium Bicarbonate + Febuxostat | Shenzhen Traditional Chinese Medicine Hospital, the Fourth Clinical Medical College of Guangzhou University of Chinese Medicine; Shenzhen Traditional Chinese Medicine Hospital, the Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, The Sanming Project of Medicine in Shenzhen | gout | | | | |
ChiCTR2300071056: Clinical Observation on the Therapeutic Effect of Jianpi Shenshi Granule on Gout Stone (Spleen Deficiency and Dampness Resistance Type) |
|
|
| Not yet recruiting | N/A | 40 | | Febuxostat + Jianpi Shenshi Granule ;Febuxostat | The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine; The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine, Base funds | Gout Stone | | | | |
NCT04697602: Low-dose Colchicine With or Without Stepwise Dose Titration of Febuxostat for Flare Prophylaxis in Gout |
|
|
| Terminated | N/A | 21 | RoW | Stepwise dose titration of febuxostat and low-dose colchicine, Fixed dose febuxostat and low-dose colchicine | National Taiwan University Hospital, National Taiwan University Hospital, Yun-Lin Branch | Gout | 08/23 | 08/23 | | |
ChiCTR2200060680: A double-blind randomized controlled trial of Qizhi Tongfeng Granule in the treatment of chronic refractory gout |
|
|
| Not yet recruiting | N/A | 40 | | Febuxostat tablet 40mg once a day + Qizhi Gout granules, 1 dose a day, divided into 2 times, orally. ;Febuxostat tablet 40mg once a day + Qizhi gout granule placebo, 1 dose, 2 times a day, orally. | Fangshan Hospital Affiliated to Beijing University of Chinese Medicine; Fangshan Hospital Affiliated to Beijing University of Chinese Medicine, Capital Health development Scientific Research Independent innovation Project | Gout | | | | |
ChiCTR2400083067: A randomized controlled trial of Qizhi gout granule in the treatment of patients with chronic gout |
|
|
| Not yet recruiting | N/A | 80 | | "Qizhi gout granules" decoction, one dose daily, divided into two administrations, taken orally.; Febuxostat tablet 20mg once a day | Fangshan Hospital Affiliated to Beijing University of Chinese Medicine; Fangshan Hospital Affiliated to Beijing University of Chinese Medicine, Beijing University of Chinese Medicine New Faculty start-up Fund project | Gout | | | | |
ChiCTR2300073188: Clinical and Mechanism Study on Qifu Huazhuo Formula in Treating intercritical gout and chronic gouty arthritis |
|
|
| Recruiting | N/A | 90 | | Febuxostat (40mg/dose, once daily, oral); Qifu Huazhuo Formula (250ml/time, twice a day, oral); Febuxostat (40mg/dose, once daily, oral)+Qifu Huazhuo Formula (250ml/dose, twice daily, oral) | Guangdong Provincial Hospital of Chinese Medicine; Zhuhai Hospital of Guangdong Provincial Hospital of Traditional Chinese Medicine, raise independently | gout | | | | |
ChiCTR2300071108: Clinical observation and network pharmacological analysis of modified Simiao Decoction in the treatment of damp-heat intrinsic gout |
|
|
| Not yet recruiting | N/A | 120 | | Febuxostat was taken orally 20mg/ day for 24 weeks ;Modified Simiao Decoction 100ml morning and evening 2 times oral; Meanwhile, febuxostat was taken orally 20mg/ day in combination. All took the drug for 24 weeks. | Shanghai Changning Tianshan Traditional Chinese Medicine Hospital; Science and Technology Commission of Changning District of Shanghai, Appropriated by Science and Technology Commission of Changning District, Shanghai. Matching Funds of Shanghai Changning Tianshan Traditional Chinese Medicine Hospital | Gout | | | | |
ChiCTR2400084417: Quzhuo Tongbi Formula prevents gout flares in the process of ULT A randomized controlled clinical trial |
|
|
| Not yet recruiting | N/A | 144 | | Quzhuo Tongbi Granules+Febuxostat; Chinese herbal placebo+Febuxostat | Zhejiang Chinese Medical University; Zhejiang Chinese Medical University, GK2024 Provincial Traditional Chinese Medicine Research Project (24-134) | gout | | | | |
| Not yet recruiting | N/A | 200 | NA | Febuxostat | Assiut University | Hyperuricemia, Diabetic Nephropathies | 04/22 | 12/22 | | |